Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
Emerging roles of exosomes in neuron-glia communication.
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis.]
Clinical Assessment of Orofacial Manifestations in 500 Patients With Multiple Sclerosis.
Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis.
Epstein-Barr virus, latitude and multiple sclerosis.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
In Vivo Brain MR Imaging at Subnanoliter Resolution: Contrast and Histology.
Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.
Twin studies and the heritability of MS: a conclusion.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
The next generation of exoskeletons: lighter, cheaper devices are in the works.
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.
Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
Dual role of Response gene to complement-32 in multiple sclerosis.
MAIT cells in autoimmunity.
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
[Posture disorders in patients with multiple sclerosis.]
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Clinical assessment of noninvasive intracranial pressure absolute value measurement method.
[Gluten-related disorders and demyelinating diseases.]

Pages